Alector (ALEC) Amortization of Deferred Charges (2025 - 2026)
Alector's (ALEC) quarterly Amortization of Deferred Charges came in at $78000.0 in Q1 2026, up 13.04% year-on-year from $69000.0 in Q1 2025, and little changed on a QoQ basis from $78000.0 in Q4 2025.
Alector (ALEC) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
Alector (ALEC) has 2 years of Amortization of Deferred Charges data on file, last reported at $78000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 13.04% year-over-year to $78000.0 in Q1 2026; TTM through Mar 2026 was $302000.0, a 337.68% increase from a year earlier, with the FY2025 full-year figure at $293000.0, changed N/A from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $78000.0, roughly flat from $78000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for ALEC reached as high as $78000.0 in Q4 2025 and fell as low as $69000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alector | 164.78 Mn | -41.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78,000.00 |
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 69,000.00 |
| Mar 31, 2025 | 69,000.00 |